Pillai K - Search Results

1

Diffuse malignant peritoneal mesothelioma--an update on treatment.

Mirarabshahii P, Pillai K, Chua TC, Pourgholami MH, Morris DL. Mirarabshahii P, et al. Among authors: pillai k. Cancer Treat Rev. 2012 Oct;38(6):605-12. doi: 10.1016/j.ctrv.2011.10.006. Epub 2011 Nov 21. Cancer Treat Rev. 2012. PMID: 22104079 Review.

2

A formulation for in situ lysis of mucin secreted in pseudomyxoma peritonei.

Pillai K, Akhter J, Chua TC, Morris DL. Pillai K, et al. Int J Cancer. 2014 Jan 15;134(2):478-86. doi: 10.1002/ijc.28380. Epub 2013 Aug 7. Int J Cancer. 2014. PMID: 23843173

3

Ki67-BCL2 index in prognosis of malignant peritoneal mesothelioma.

Pillai K, Pourgholami MH, Chua TC, Morris DL. Pillai K, et al. Am J Cancer Res. 2013 Aug 14;3(4):411-23. eCollection 2013. Am J Cancer Res. 2013. PMID: 23977450 Free PMC article.

4

Monepantel considerably enhances the therapeutic potentials of PEGylated liposomal doxorubicin and gemcitabine in ovarian cancer: in vitro and in vivo studies.

Ataie-Kachoie P, Pillai K, Badar S, Akhter J, Morris DL. Ataie-Kachoie P, et al. Among authors: pillai k. Am J Cancer Res. 2018 Oct 1;8(10):2064-2075. eCollection 2018. Am J Cancer Res. 2018. PMID: 30416856 Free PMC article.

5

Prognostic significance of Ki67 expression in malignant peritoneal mesothelioma.

Pillai K, Pourgholami MH, Chua TC, Morris DL. Pillai K, et al. Am J Clin Oncol. 2015 Aug;38(4):388-94. doi: 10.1097/COC.0b013e3182a0e867. Am J Clin Oncol. 2015. PMID: 26214083

6

Efficacy of a novel mucolytic agent on pseudomyxoma peritonei mucin, with potential for treatment through peritoneal catheters.

Akhter J, Pillai K, Chua TC, Alzarin N, Morris DL. Akhter J, et al. Among authors: pillai k. Am J Cancer Res. 2014 Sep 6;4(5):495-507. eCollection 2014. Am J Cancer Res. 2014. PMID: 25232491 Free PMC article.

7

Anticancer effect of bromelain with and without cisplatin or 5-FU on malignant peritoneal mesothelioma cells.

Pillai K, Ehteda A, Akhter J, Chua TC, Morris DL. Pillai K, et al. Anticancer Drugs. 2014 Feb;25(2):150-60. doi: 10.1097/CAD.0000000000000039. Anticancer Drugs. 2014. PMID: 24366282

8

Does the expression of BCL2 have prognostic significance in malignant peritoneal mesothelioma?

Pillai K, Pourgholami MH, Chua TC, Morris DL. Pillai K, et al. Am J Cancer Res. 2013 Jun 20;3(3):312-22. Print 2013. Am J Cancer Res. 2013. PMID: 23841030 Free PMC article.

9

MUC1 has prognostic significance in malignant peritoneal mesothelioma.

Pillai K, Pourgholami MH, Chua TC, Morris DL. Pillai K, et al. Int J Biol Markers. 2013 Sep 27;28(3):303-12. doi: 10.5301/jbm.5000038. Int J Biol Markers. 2013. PMID: 23828409

10

Oestrogen receptors are prognostic factors in malignant peritoneal mesothelioma.

Pillai K, Pourgholami MH, Chua TC, Morris DL. Pillai K, et al. J Cancer Res Clin Oncol. 2013 Jun;139(6):987-94. doi: 10.1007/s00432-013-1408-2. Epub 2013 Mar 6. J Cancer Res Clin Oncol. 2013. PMID: 23463097

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results